Reata had a phase 3 trial for Chronic Kidney Disease, unfortunately FDA knocked it back in 2021, caused their share price down to $28, currently their pipeline is shown as follows from their website,
So, it's apparently Reata's main drug is Skyclarys which is very very similar to NEU's Daybue. Reata's other pipelines are relatively at early stages, compared with NEU's pipeline,
Here's my summary,
Reata is being acquired by Biogen for US$7.3 billion.
Obviously, NEU has Acadia as distribution partner, so valuation will be shared between NEU and Acadia. On the other hand, NEU will not incur much expenses for selling DAYBUE as NEU is to receive up to US$865m milestone payments and plus 10% to mid 20% royalties on every net sales, all those future payments will be pre-tax profit.
This year, NEU has already received US$150m milestone payments from Acadia, first royalty payment will flow this quarter.
All IMO, always do your own research, HC posts are just personal opinions.
GLTA.
NEU Price at posting:
$11.76 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)